TSHA a medtech penny stock pumps on news and earnings LONG
TSHA is a gene technology medical company which reported on its clinical trials for Rett
Syndrome which is a neurobehavioral disorder separate from others like autism or
schizophrenia. This could be a breakthrough medication for those who suffer from Rett.
TSHA102 could be heralded as a miracle treatment ( not a cure). Price had trended up
in February and then down in March and is now situated at the mean anchored VWAP.
Relative volumes are 5-10X the running mean. I am taking a sizeable position here based
also on my background as well as the forecasts of medical technology stocks as being hot right
now especially small caps. Risk is definitely on. TSHA has been selling off parts of its pipeline
to fortify its core. This tells me leadership is realistic and has a survival plan which is a big plus
in the world of young and small medical technology companies. The earnings report from
yesterday showed a big earnings beat and a transition from cash burning to positive earnings.
Part of this is from selling off part of its future. Nonetheless, that future may be very bright
with what remains. I believe that TSHA will consolidate and gain consensus as to fair value
but then resume bullish continuation. This may be a buy and hold until the next earnings while
watching for clinical trial news that will give a hint as to the growth path.
Syndrome which is a neurobehavioral disorder separate from others like autism or
schizophrenia. This could be a breakthrough medication for those who suffer from Rett.
TSHA102 could be heralded as a miracle treatment ( not a cure). Price had trended up
in February and then down in March and is now situated at the mean anchored VWAP.
Relative volumes are 5-10X the running mean. I am taking a sizeable position here based
also on my background as well as the forecasts of medical technology stocks as being hot right
now especially small caps. Risk is definitely on. TSHA has been selling off parts of its pipeline
to fortify its core. This tells me leadership is realistic and has a survival plan which is a big plus
in the world of young and small medical technology companies. The earnings report from
yesterday showed a big earnings beat and a transition from cash burning to positive earnings.
Part of this is from selling off part of its future. Nonetheless, that future may be very bright
with what remains. I believe that TSHA will consolidate and gain consensus as to fair value
but then resume bullish continuation. This may be a buy and hold until the next earnings while
watching for clinical trial news that will give a hint as to the growth path.
Trade active:
Initial Target shown here
Trade active:
Trade is off to a good start as the stop loss is now raised above break-even with
the morning momentum underway. Risk and stress free. No profit realized yet- full
position into the weekend.
the morning momentum underway. Risk and stress free. No profit realized yet- full
position into the weekend.
Comment:
35% in 3 days is there more or should I trim some before the weekend?